Octavian Therapeutics ("Octavian" or "the Company"), a leading clinical-stage innovator in neuropathic pain treatment, today announces a transformative rebrand, the appointment of a new Non-Executive ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

UAE-based biotech startup BioSapien has extended its pre-Series A funding round to $7 million.The extension – which comes ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...

Giving patients with a common form of breast cancer an immunotherapy drug before surgery appears to boost outcomes, a n ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations were $5.04. Operator: My name is Julienne, and I will be your conference ...

Most patients received prior relapsed/metastatic phase chemotherapy (92.4%), 29.1% received frontline chemotherapy, and 43.3% were pre- or perimenopausal. The trial’s primary end point was ...

You start by selecting a pet insurance policy that aligns with your dog’s healthcare needs and your budget. You then pay a ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...